(a) In March 2021, Cyclotek CMO, Dr Rob Ware together with co-applicants AANMS submit the final health economics and assessment of the PET/CT PSMA imaging application into MSAC.
(b) Cyclotek’s Group Operations Manager, Rebecca Dodgson executes MasterControl at our Queensland facility. MasterControl is a document management program that when fully deployed across the group will contain our entire documentation management system for better functionality and performance.
(c) Collaboration between researchers at Monash Institute of Pharmaceutical Science and Cyclotek’s product development team have been successful with a novel 18F labelling of a drug used in Prostate Cancer to which may provide a better patient management tool for prognostic assessment.
(d) Cyclotek in New Zealand validate 18F FBB (Florbetaben) at our Wellington facility for use in clinical trials and clinical diagnostics. Contracts with Pacific Radiology and Ascot Radiology have been activated with first in-country supply scheduled for 5 July 2021.
[contact-form-7 id=”714″ title=”Update Form”]
